South San Francisco-based Denali Therapeutics Inc.'s dosing of the first patient in a phase Ib study with DNL-201 for Parkinson's disease (PD) brought renewed attention to the affliction and to the race with Glaxosmithkline plc (GSK), of London, in the development of leucine-rich repeat kinase 2 (LRRK2) inhibitors. Read More
Imprimis Pharmaceuticals Inc., of San Diego, has changed its name to Harrow Health Inc. and will now trade on Nasdaq under the symbol HROW. The company will continue to operate its ophthalmology-focused compounding business as a subsidiary under the name Imprimisrx. Read More
Aytu Bioscience Inc., of Englewood. Colo., said Armistice Capital has invested $5 million in the company in the form of a three-year senior secured note. The investment was made in conjunction with the company's licensing of Tuzistra XR (codeine polistirex/chlorpheniramine polistirex) and a complementary antitussive pending FDA approval and is intended to further support the growth of the company's commercial portfolio. Read More
TAIPEI, Taiwan – Taiwan startup Sinew Pharma Inc. is developing what it hopes will be a first-in-class drug to treat nonalcoholic steatohepatitis (NASH). With an investigational new drug (IND) approval by the U.S. FDA under its belt, Sinew plans to advance its core product to a phase IIb study next year. Read More
HONG KONG – Five years into the partnership with Eli Lilly and Co., an amendment in late December to their license agreement lets Hutchison China Meditech Ltd. (Chi-Med) take a larger role in the development and commercialization of fruquintinib in China. Read More
HONG KONG – Chugai Pharmaceutical Co. Ltd. is ending the year on a winning streak. The Japanese pharmaceutical company recently reported that its satralizumab had achieved the primary endpoint in a phase III monotherapy study in neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments. Read More
